智翔金泰：GR1803注射液系统性红斑狼疮适应症获得药物临床试验批准通知书

Core Viewpoint - The company, Zhixiang Jintai (688443.SH), has received approval from the National Medical Products Administration for the clinical trial of its self-developed drug GR1803 injection for the treatment of systemic lupus erythematosus (SLE) [1] Group 1: Company Information - GR1803 injection is a bispecific antibody drug targeting BCMA and CD3, classified as a Class 1 therapeutic biological product [1] - The drug aims to treat autoimmune diseases mediated by B cells, specifically targeting the activation of CD3+ T cells to induce the lysis of BCMA+ cells [1] Group 2: Industry Context - Systemic lupus erythematosus (SLE) is a systemic autoimmune disease where autoimmune B cells play a significant role in its development [1]